These Analysts Revise Their Forecasts On GH Research After Q1 Results

GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.

Benzinga • May 15, 2026

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study enrolment completed Cash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026 Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Updates Scientific Presentations and Publications In March 2026, the results of our Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry.

GlobeNewsWire • May 14, 2026

GH Research Announces Pricing of $117.5 Million Underwritten Offering

DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares are being offered by GH Research PLC.

GlobeNewsWire • Apr 29, 2026

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health ​regulators to speed up reviews of psychedelic drugs and boosted ‌federal research funding.

Reuters • Apr 20, 2026

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness.

GlobeNewsWire • Apr 20, 2026

How Trump's psychedelics executive order could unlock stalled cannabis reform

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status, but reinforces a federal move toward medical, evidence-based framework for other alternative medicines, like cannabis, experts say.

CNBC • Apr 20, 2026

Psychedelics stocks rise after Trump order expands research, access pathways

Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating research into psychedelic-assisted therapies and expanding patient access for certain serious mental health conditions, including post-traumatic stress disorder (PTSD) and treatment-resistant depression. The executive order, signed by Trump on Saturday, directs the US Food and Drug Administration (FDA) Commissioner to prioritize review pathways for psychedelic drugs that have received Breakthrough Therapy designation for serious mental illnesses and meet criteria under a national voucher program designed to speed regulatory review.

Proactive Investors • Apr 20, 2026

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has been backed by Republicans in Texas in recent years who argue in favor of ibogaine's success with veterans.

Forbes • Apr 20, 2026

Psychedelic stocks rally with Trump's support

An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.

Market Watch • Apr 20, 2026

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.

Barrons • Apr 20, 2026